- Home
- MUE vs NYXH Comparison
MUE vs NYXH Comparison
Compare MUE & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MUE | NYXH |
|---|---|---|
| Founded | 1999 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 221.2M | 188.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MUE | NYXH |
|---|---|---|
| Price | $10.04 | $4.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $12.67 |
| AVG Volume (30 Days) | ★ 62.6K | 56.8K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 4.09% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,616,215.00 |
| Revenue This Year | N/A | $85.62 |
| Revenue Next Year | N/A | $320.09 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 10.96 |
| 52 Week Low | $8.53 | $4.35 |
| 52 Week High | $10.17 | $11.87 |
Technical Indicators
Market Signals| Indicator | MUE | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 52.64 | 42.71 |
| Support Level | $9.91 | $4.53 |
| Resistance Level | $9.99 | $5.01 |
| Average True Range (ATR) | 0.08 | 0.29 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 45.66 | 18.28 |
Price Performance
Historical ComparisonAbout MUE Blackrock MuniHoldings Quality Fund II Inc.
BlackRock MuniHoldings Quality Fund II Inc is a diversified, closed-end management investment company. The fund's investment objective is to provide shareholders with current income exempt from U.S. federal income taxes. The Trust seeks to achieve its investment objective by investing principally in long-term, investment-grade municipal obligations exempt from U.S. federal income taxes. Under normal market conditions, the Trust invests at least 80% of its assets in municipal obligations with remaining maturities of one year or more at the time of investment.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.